<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04463290</url>
  </required_header>
  <id_info>
    <org_study_id>197/17.6.2020</org_study_id>
    <nct_id>NCT04463290</nct_id>
  </id_info>
  <brief_title>Association of SNPs in Metalloproteinases (MMPs) Genes With the Risk of Primary Knee Osteoarthritis in Greek Population.</brief_title>
  <official_title>Association of Single Nucleotide Polymorphisms in Metalloproteinases (MMPs) Genes With the Risk of Primary Knee Osteoarthritis in Greek Population.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Does the presence of gene polymorphisms -1575G / A in the MMP-2 gene, 836A / G in the MMP-9
      gene and -77A / G in the MMP-13 gene, affect the risk of developing idiopathic knee
      osteoarthritis in the Greek population?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective case-control study in which the patients' genotype will be studied
      against the genotype of the controls. The study is prospective and not retrospective, as data
      will be collected from patients with primary knee osteoarthritis as well as the control group
      from the outset. The study intends to includ 200 people. The first group consists of 100
      individuals suffering from knee osteoarthritis, while the second group will include 100
      healthy controls without osteoarthritis. From each one DNA will be isolated and analyzed from
      collected blood. The prospective study allows valid data to be collected on patient
      demographics and disease severity. Due to the large number of cases of the disease, it is
      estimated that the necessary specimens will be collected within a reasonable time from the
      beginning of this thesis. The choice of the patient-control study is necessary to limit the
      influence of confounding factors (age, gender, obesity, etc.). This type of study includes
      rigorous selection of patients and controls with specific entry and exclusion criteria,
      selection of controls based on matching patient characteristics, stratification, and subgroup
      analyzes. The final result will be a comparison of the incidence of specific gene
      polymorphisms between patients with knee osteoarthritis and the normal population.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 6, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The frequensy of presence of gene polymorphisms -1575G / A MMP-2 gene, 836A / G MMP-9 gene and -77A / G MMP-13 gene, in Greek patients with knee osteoarthritis comparing with healthy people</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Metalloproteinase SNPs -1575 G/A MMP-2, 836 A/G MMP-9 and -77 A/G MMP-13 and Risk for Developing Knee Osteoarthritis in Greek Population</condition>
  <arm_group>
    <arm_group_label>Knee Osteoarthritis Patients Group</arm_group_label>
    <description>Patients suffering from primary knee osteoarthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Healthy people without suffering from primary knee osteoarthritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention, Patients selection based on clinical symptoms and radiological imaging</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Knee Osteoarthritis Patients Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      2ml blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will take place at the 3rd Orthopedic Department of Aristotle University of
        Thessaloniki of the Papageorgiou General Hospital of Thessaloniki. The patients group will
        be patients with primary knee osteoarthritis coming for first examination for knee pain or
        for sceduled total knee arthroplasty surgery. The control group will be people coming for
        examination due to accident (trauma, fracture) or anything else not relevant with knee
        pain. Both groups must not have any of the exclusion criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primary knee osteoarthritis are selected based on clinical symptoms and
             radiological imaging with a score at least 2 on the Kellgren &amp; Lawrence scale.

          -  Patients without symptomatology or radiographic image of knee osteoarthritis (score &lt;2
             on Kellgren &amp; Lawrence scale) will be selected as controls.

        Exclusion Criteria:

          -  systemic inflammatory disease

          -  rheumatic disease

          -  liver disease

          -  renal failure

          -  neoplasm or other chronic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleftherios Tsiridis, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Aristotle University of Thessaloniki, 3rd Orthopaedic Department, Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christos Milaras, Phd Cand.</last_name>
    <phone>+306942267715</phone>
    <email>mil1384@yahoo.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eleftherios Tsiridis, Professor</last_name>
    <phone>+302313323702</phone>
    <email>g.orthop@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Shi J, Son MY, Yamada S, Szabova L, Kahan S, Chrysovergis K, Wolf L, Surmak A, Holmbeck K. Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis. Dev Biol. 2008 Jan 1;313(1):196-209. Epub 2007 Oct 23.</citation>
    <PMID>18022611</PMID>
  </reference>
  <reference>
    <citation>Hattori N, Mochizuki S, Kishi K, Nakajima T, Takaishi H, D'Armiento J, Okada Y. MMP-13 plays a role in keratinocyte migration, angiogenesis, and contraction in mouse skin wound healing. Am J Pathol. 2009 Aug;175(2):533-46. doi: 10.2353/ajpath.2009.081080. Epub 2009 Jul 9.</citation>
    <PMID>19590036</PMID>
  </reference>
  <reference>
    <citation>Salo T, Mäkelä M, Kylmäniemi M, Autio-Harmainen H, Larjava H. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest. 1994 Feb;70(2):176-82.</citation>
    <PMID>8139259</PMID>
  </reference>
  <reference>
    <citation>Duerr S, Stremme S, Soeder S, Bau B, Aigner T. MMP-2/gelatinase A is a gene product of human adult articular chondrocytes and is increased in osteoarthritic cartilage. Clin Exp Rheumatol. 2004 Sep-Oct;22(5):603-8.</citation>
    <PMID>15485014</PMID>
  </reference>
  <reference>
    <citation>Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998 May 1;93(3):411-22.</citation>
    <PMID>9590175</PMID>
  </reference>
  <reference>
    <citation>Söder S, Roach HI, Oehler S, Bau B, Haag J, Aigner T. MMP-9/gelatinase B is a gene product of human adult articular chondrocytes and increased in osteoarthritic cartilage. Clin Exp Rheumatol. 2006 May-Jun;24(3):302-4.</citation>
    <PMID>16870098</PMID>
  </reference>
  <reference>
    <citation>Dreier R, Grässel S, Fuchs S, Schaumburger J, Bruckner P. Pro-MMP-9 is a specific macrophage product and is activated by osteoarthritic chondrocytes via MMP-3 or a MT1-MMP/MMP-13 cascade. Exp Cell Res. 2004 Jul 15;297(2):303-12.</citation>
    <PMID>15212936</PMID>
  </reference>
  <reference>
    <citation>Zeng GQ, Chen AB, Li W, Song JH, Gao CY. High MMP-1, MMP-2, and MMP-9 protein levels in osteoarthritis. Genet Mol Res. 2015 Nov 23;14(4):14811-22. doi: 10.4238/2015.November.18.46.</citation>
    <PMID>26600542</PMID>
  </reference>
  <reference>
    <citation>Shiomi T, Lemaître V, D'Armiento J, Okada Y. Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol Int. 2010 Jul;60(7):477-96. doi: 10.1111/j.1440-1827.2010.02547.x. Review.</citation>
    <PMID>20594269</PMID>
  </reference>
  <reference>
    <citation>Li H, Wang D, Yuan Y, Min J. New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis. Arthritis Res Ther. 2017 Nov 10;19(1):248. doi: 10.1186/s13075-017-1454-2. Review.</citation>
    <PMID>29126436</PMID>
  </reference>
  <reference>
    <citation>Harendza S, Lovett DH, Panzer U, Lukacs Z, Kuhnl P, Stahl RA. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem. 2003 Jun 6;278(23):20490-9. Epub 2003 Mar 25.</citation>
    <PMID>12657623</PMID>
  </reference>
  <reference>
    <citation>Beber AR, Polina ER, Biolo A, Santos BL, Gomes DC, La Porta VL, Olsen V, Clausell N, Rohde LE, Santos KG. Matrix Metalloproteinase-2 Polymorphisms in Chronic Heart Failure: Relationship with Susceptibility and Long-Term Survival. PLoS One. 2016 Aug 23;11(8):e0161666. doi: 10.1371/journal.pone.0161666. eCollection 2016.</citation>
    <PMID>27551966</PMID>
  </reference>
  <reference>
    <citation>Hua Y, Song L, Wu N, Xie G, Lu X, Fan X, Meng X, Gu D, Yang Y. Polymorphisms of MMP-2 gene are associated with systolic heart failure prognosis. Clin Chim Acta. 2009 Jun 27;404(2):119-23. doi: 10.1016/j.cca.2009.03.030. Epub 2009 Mar 28.</citation>
    <PMID>19332048</PMID>
  </reference>
  <reference>
    <citation>Morgan AR, Han DY, Thompson JM, Mitchell EA, Ferguson LR. Analysis of MMP2 promoter polymorphisms in childhood obesity. BMC Res Notes. 2011 Jul 21;4:253. doi: 10.1186/1756-0500-4-253.</citation>
    <PMID>21777433</PMID>
  </reference>
  <reference>
    <citation>Mossböck G, Weger M, Faschinger C, Zimmermann C, Schmut O, Renner W, El-Shabrawi Y. Role of functional single nucleotide polymorphisms of MMP1, MMP2, and MMP9 in open angle glaucomas. Mol Vis. 2010 Aug 28;16:1764-70.</citation>
    <PMID>20808730</PMID>
  </reference>
  <reference>
    <citation>Park YS, Jeon YJ, Kim HS, Han IB, Oh SH, Kim DS, Kim NK. The GC + CC genotype at position -418 in TIMP-2 promoter and the -1575GA/-1306CC genotype in MMP-2 is genetic predisposing factors for prevalence of moyamoya disease. BMC Neurol. 2014 Oct 4;14:180. doi: 10.1186/s12883-014-0180-5.</citation>
    <PMID>25280484</PMID>
  </reference>
  <reference>
    <citation>Pérez-Hernández N, Vargas-Alarcón G, Martínez-Rodríguez N, Martínez-Ríos MA, Peña-Duque MA, Peña-Díaz Ade L, Valente-Acosta B, Posadas-Romero C, Medina A, Rodríguez-Pérez JM. The matrix metalloproteinase 2-1575 gene polymorphism is associated with the risk of developing myocardial infarction in Mexican patients. J Atheroscler Thromb. 2012;19(8):718-27. Epub 2012 Jun 27.</citation>
    <PMID>22785600</PMID>
  </reference>
  <reference>
    <citation>Sabbatini AR, Barbaro NR, de Faria AP, Ritter AMV, Modolo R, Correa NB, Brunelli V, Pinho C, Fontana V, Moreno H. Matrix metalloproteinase-2 -735C/T polymorphism is associated with resistant hypertension in a specialized outpatient clinic in Brazil. Gene. 2017 Jul 15;620:23-29. doi: 10.1016/j.gene.2017.04.004. Epub 2017 Apr 5.</citation>
    <PMID>28390988</PMID>
  </reference>
  <reference>
    <citation>Štrbac D, Goričar K, Dolžan V, Kovač V. Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma. Dis Markers. 2017;2017:8069529. doi: 10.1155/2017/8069529. Epub 2017 Sep 12.</citation>
    <PMID>29138529</PMID>
  </reference>
  <reference>
    <citation>Saravani S, Yari D, Saravani R, Azadi Ahmadabadi C. Association of COL4A3 (rs55703767), MMP-9 (rs17576)and TIMP-1 (rs6609533) gene polymorphisms with susceptibility to type 2 diabetes. Biomed Rep. 2017 Mar;6(3):329-334. doi: 10.3892/br.2017.856. Epub 2017 Feb 9.</citation>
    <PMID>28451395</PMID>
  </reference>
  <reference>
    <citation>Chen X, Chen Y, Wiggs JL, Pasquale LR, Sun X, Fan BJ. Association of Matrix Metalloproteinase-9 (MMP9) Variants with Primary Angle Closure and Primary Angle Closure Glaucoma. PLoS One. 2016 Jun 7;11(6):e0157093. doi: 10.1371/journal.pone.0157093. eCollection 2016.</citation>
    <PMID>27272641</PMID>
  </reference>
  <reference>
    <citation>Wu HD, Bai X, Chen DM, Cao HY, Qin L. Association of genetic polymorphisms in matrix metalloproteinase-9 and coronary artery disease in the Chinese Han population: a case-control study. Genet Test Mol Biomarkers. 2013 Sep;17(9):707-12. doi: 10.1089/gtmb.2013.0109. Epub 2013 Jul 2.</citation>
    <PMID>23819814</PMID>
  </reference>
  <reference>
    <citation>Rose BJ, Kooyman DL. A Tale of Two Joints: The Role of Matrix Metalloproteases in Cartilage Biology. Dis Markers. 2016;2016:4895050. doi: 10.1155/2016/4895050. Epub 2016 Jul 13. Review.</citation>
    <PMID>27478294</PMID>
  </reference>
  <reference>
    <citation>Takashiba S, Naruishi K. Gene polymorphisms in periodontal health and disease. Periodontol 2000. 2006;40:94-106. Review.</citation>
    <PMID>16398687</PMID>
  </reference>
  <reference>
    <citation>Yoon S, Kuivaniemi H, Gatalica Z, Olson JM, Butticè G, Ye S, Norris BA, Malcom GT, Strong JP, Tromp G. MMP13 promoter polymorphism is associated with atherosclerosis in the abdominal aorta of young black males. Matrix Biol. 2002 Oct;21(6):487-98.</citation>
    <PMID>12392760</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 5, 2020</study_first_submitted>
  <study_first_submitted_qc>July 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>July 5, 2020</last_update_submitted>
  <last_update_submitted_qc>July 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Christos Milaras</investigator_full_name>
    <investigator_title>Orthopaedic Surgeon, Phd Candidate</investigator_title>
  </responsible_party>
  <keyword>MMPs , SNPs, Knee osteoarthritis, -1575G/A MMP-2 , 836A/G MMP-9 , -77A/G MMP-13</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data that will be shared will be all the demographic data of the participants (gender, age, etc.) and the study results data. Personal participants data as name, adress, telephone number will not be shared for any reason.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>12 months after publication</ipd_time_frame>
    <ipd_access_criteria>Investigators from Greece, after personal contact.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

